Literature DB >> 19654083

[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase].

P Joly1, C Bon, A Francina, M-C Gelineau, P Lacan, H Orfeuvre.   

Abstract

We present here the case-report of a man with a severe G6PD deficiency revealed after the use of rasburicase (uricolytic drug) during a chemotherapy protocol. The genotypic analysis done to confirm the biochemical measurement revealed the 'Mediterranean mutation' at the hemizygous state (G6PD gene is located on chromosome X). Consequently to this diagnose, a search for G6PD deficiency has been performed (at the biochemical and genotypic levels) for the 9 children (7 daughters and 2 sons) of the proband. Surprisingly, one of his son was found to be hemizygous for the mediterranean mutation and one of his daughter appeared homozygous for this same mutation. This implies that the proband's wife (not studied) is certainly heterozygous for the mediterranean mutation, as it is very unlikely that this mutation had appeared de novo for two children of this couple.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654083     DOI: 10.1684/abc.2009.0353

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  2 in total

1.  PharmGKB summary: very important pharmacogene information for G6PD.

Authors:  Ellen M McDonagh; Caroline F Thorn; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

Review 2.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.